Ming Zhou

Ming Zhou currently serves as the Sr Director of Oligonucleotide Process Chemistry at Entrada Therapeutics, leading a team focused on API materials to advance discovery research and preclinical studies. Prior experience includes serving as Principal Scientist at Sarepta Therapeutics, where design and modification of Phosphorodiamidate Morpholino Oligomer (PMO) and cell-penetrating peptides for therapeutic applications were key responsibilities. Ming also worked as a Research Scientist at Joyant Pharmaceuticals, contributing to the design and synthesis of Diazonamides analogs and innovating Smac peptidomimetics. Earlier academic roles included postdoctoral fellowships at Baylor University and The University of Texas at Arlington after earning a Ph.D. in Organic Chemistry from Toyo University.